IMUGENE LIMITED

0.00%

1.5¢

Market Cap $112.0M

Healthcare Biotechnology

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. WEBINAR: What investors should know about what it takes for ASX-listed companies to get medical developments...

Latest Threads

Tag

Subject

IMU

Ann: Consolidation/Split - IMU

17:02

21K

17:02

Last post AlCp

21K

IMU

Why IMU is a multi multi bagger

525 526 527

16:32

31K

15M

16:32

Last post AlCp

31K

15M

IMU Biotech

IMUGENE CHART. TA only

621 622 623

11/06/25

37K

19M

11/06/25

Last post Fid

37K

19M

IMU

Media Thread

301 302 303

10/06/25

18K

8.7M

10/06/25

Last post RA61

18K

8.7M

IMU

No to sell and move on Yes to perennial whinging

10/06/25

2.5K

10/06/25

Last post RA61

2.5K

IMU

Ann: Notification of cessation of securities - IMU

06/06/25

2.9K

06/06/25

Last post Ianwil

2.9K

IMU

NO consolidation YES raise.

06/06/25

12K

06/06/25

Last post Devildamian

12K

IMU

IMUOE are in the money

06/06/25

40K

06/06/25

Last post Steini

40K

See All Discussions

Timeline

Notification of cessation of securities - IMU
06 Jun 16:22	Share

1st Australian site activated PD1-Vaxx Neo-POLEM Ph II trial
02 Jun 09:12	Share

Dr John Byon appointed Chief Medical Officer
30 May 09:57	Share

Consolidation/Split - IMU
29 May 10:16	Share

Letter to Imugene Shareholders
28 May 09:33	Share

Addendum to Notice of Extraordinary General Meeting
27 May 18:12	Share

Notice of Extraordinary General Meeting/Proxy Form
27 May 12:47	Share

Notification regarding unquoted securities - IMU
23 May 16:11	Share

Notification of cessation of securities - IMU
21 May 16:42	Share

Proposed Consolidation of Capital
16 May 12:56	Share

Letter to Shareholders
01 May 11:59	Share

Quarterly Activities/Appendix 4C Cash Flow Report
30 Apr 08:47	Share

Application for quotation of securities - IMU
14 Apr 16:45	Share

Notification of cessation of securities - IMU
11 Apr 16:55	Share

Notification regarding unquoted securities - IMU
11 Apr 16:50	Share

Investor Update & FAQ Webinar
10 Apr 09:35	Share

1st dose level cleared IV combination arm onCARlytics trial
03 Apr 08:51	Share

Azer-cel Granted FDA Fast Track Designation in Blood Cancer
19 Mar 09:02	Share

Application for quotation of securities - IMU
13 Mar 17:51	Share

S&P DJI Announces March 2025 Quarterly Rebalance
07 Mar 17:01	Share

Darren Keamy Appointed CFO and Company Secretary
04 Mar 09:01	Share

Half Yearly Report and Accounts
28 Feb 10:00	Share

Imugene Granted India Patent for Oncolytic Virotherapy CF33
27 Feb 08:59	Share

Imugene OnCARlytics Patent Allowance in China
26 Feb 08:58	Share

Change of Directors Interest Notice x 5
21 Feb 16:53	Share

Notification regarding unquoted securities - IMU
21 Feb 16:46	Share

Application for quotation of securities - IMU
21 Feb 16:45	Share

Azer-cel demonstrates two additional Complete Responses
14 Feb 08:44	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Jan 08:50	Share

Notification of cessation of securities - IMU
29 Jan 16:58	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.5¢		Change 0.000(0.00%)		Mkt cap ! $112.0M

Open	High	Low	Value	Volume
1.5¢	1.6¢	1.4¢	$125.4K	8.369M

Buyers (Bids)

No.	Vol.	Price($)
76	17029463	1.4¢

Sellers (Offers)

Price($)	Vol.	No.
1.5¢	1061875	3

View Market Depth

No.	Vol.	Price($)
75	16815106	0.014
38	13733634	0.013
40	8162244	0.012
13	3263001	0.011
32	6669729	0.010

Price($)	Vol.	No.
0.015	1061875	3
0.016	12291344	35
0.017	6170154	16
0.018	6533023	29
0.019	6839697	18

Last trade - 16.10pm 13/06/2025 (20 minute delay)


Last 1.5¢		Change 0.000 ( 5.84 %)
Open	High	Low	Volume
1.6¢	1.6¢	1.5¢	5937020
Last updated 15.59pm 13/06/2025 ?

IMU (ASX) Chart

IMUGENE LIMITED

Latest Threads

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Timeline

Featured News

Latest Videos

Imugene (ASX:IMU) doses first patients in VAXINIA combination study

03 Mar 2023 14:39 (AEDT)

Imugene (ASX:IMU) receives US patent for PD1-Vaxx

10 Feb 2023 10:58 (AEDT)

Imugene (ASX:IMU) advances VAXINIA trial

02 Feb 2023 12:21 (AEDT)

Latest Articles

Yes, we burn a lot of cash: Imugene issues letter to investors as 1Y returns -72%

As it clocks one year returns down -72%, Imugene Ltd (ASX:IMU) this week issued a letter to shareholders confirming shareholders'...

First Aussie doses bring Imugene major step closer to 'quicker, cheaper' non-Hodgkin’s lymphoma care

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic CAR T-cell therapy Azer-cel treatment at the Royal Prince Alfred Hospital in Sydney earlier this week.This dosage marks the start of Imugene’s Phase 1b t...

Imugene kicks off Australian trial for blood cancer treatment

Imugene Ltd has opened its first Australian trial for a Phase 1b clinical trial to test CAR T cell therapy azer-cel

Buyers (Bids)

Sellers (Offers)

New Analyst Report Lifts Almonty Target Price to CDN$5.50

Top Stories

Featured News